New Data at AAN 2022 Highlight Real-World Evidence from Biogen’s MS Portfolio and Emerging Research on Disease Progression
04 avr. 2022 16h06 HE
|
Biogen Inc.
Data from NOVA study further support the efficacy and safety of natalizumab IV when administered every six weeks as compared to the approved every four-week dosingAdditional real-world data affirm...
Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
30 mars 2022 07h30 HE
|
Biogen Inc.
Confirmatory trial’s completion is expected in an accelerated timeline of four years with patient screening to start in MayMultiple strategies in place to enroll patients that are representative of...
Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
28 mars 2022 07h30 HE
|
Biogen Inc.
BIIB078, an investigational antisense oligonucleotide for C9orf72-associated amyotrophic lateral sclerosis (ALS), did not show clinical benefit; clinical program will be discontinuedBiogen and Ionis...
Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer’s Disease
16 mars 2022 11h54 HE
|
Biogen Inc.
CAMBRIDGE, Mass., March 16, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that The Journal of Prevention of Alzheimer’s Disease (JPAD) today published a peer-reviewed manuscript...
Long-Term Phase 3 Data Show ADUHELM® Continues to Reduce Underlying Pathologies of Alzheimer’s Disease in Patients Treated for More Than Two Years
16 mars 2022 07h30 HE
|
Biogen Inc.
ADUHELM continued to reduce two key Alzheimer’s disease pathologies, amyloid beta plaques and p-tau181, in patients treated for up to two and a half yearsData from both Phase 3 studies also show that...
Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments
14 mars 2022 19h00 HE
|
Biogen Inc.
Aducanumab collaboration to convert from Eisai sharing of global profits and losses to a global royalty arrangement, effective January 1, 2023Lecanemab collaboration to continue unchanged...
Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference
14 mars 2022 07h30 HE
|
Biogen Inc.
First patient treated in the ASCEND study evaluating the potential benefit of investigational higher dose nusinersen in children, teens and adults previously treated with Evrysdi® (risdiplam)Baseline...
Biogen to Present New Research at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2022)
11 mars 2022 16h30 HE
|
Biogen Inc.
CAMBRIDGE, Mass., March 11, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the company will present new Alzheimer’s disease research, as well as data for ADUHELM® (aducanumab-avwa)...
Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis
07 févr. 2022 16h05 HE
|
Biogen Inc.
CAMBRIDGE, Mass and SOLNA, Sweden, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Xbrane Biopharma AB (STO: XBRANE) today announced that they have entered into a commercialization...
Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody
01 févr. 2022 07h30 HE
|
Biogen Inc.
Mosunetuzumab is an investigational T-cell engaging bispecific antibody targeting CD20 and CD3 in development for B-cell non-Hodgkin’s lymphoma and other therapeutic areas CAMBRIDGE, Mass., Feb. 01,...